BR0309406A - Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento - Google Patents

Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento

Info

Publication number
BR0309406A
BR0309406A BR0309406-5A BR0309406A BR0309406A BR 0309406 A BR0309406 A BR 0309406A BR 0309406 A BR0309406 A BR 0309406A BR 0309406 A BR0309406 A BR 0309406A
Authority
BR
Brazil
Prior art keywords
inhibitor
lipase
composition
konjac
methods
Prior art date
Application number
BR0309406-5A
Other languages
English (en)
Other versions
BRPI0309406B1 (pt
Inventor
Jacques Bailly
Rainer Eugen Martin
Susanne Raab
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0309406A publication Critical patent/BR0309406A/pt
Publication of BRPI0309406B1 publication Critical patent/BRPI0309406B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, PROCESSO DE PREPARAçãO, KIT E MéTODOS PARA TRATAMENTO DE OBESIDADE, UTILIZAçãO DE COMPOSIçãO E INIBIDOR DE LìPASES, INIBIDOR DE LìPASES E GLUCOMANAN OU KONJAC E UTILIZAçãO DOS MESMOS E MéTODO DE TRATAMENTO". A presente invenção refere-se a composições e métodos para o tratamento de obesidade. Mais particularmente, a invenção refere-se a uma composição que compreende um inibidor de lípases, e konjac ou glucomanan.
BRPI0309406A 2002-04-26 2003-04-15 composição farmacêutica, processo para preparar a referida composição, kit para tratamento de obesidade e uso da referida composição na fabricação de composições úteis para o tratamento e prevenção de obesidade BRPI0309406B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02009254 2002-04-26
PCT/EP2003/003908 WO2003090742A1 (en) 2002-04-26 2003-04-15 Pharmaceutical composition comprising a lipase inhibitor and glucomannan

Publications (2)

Publication Number Publication Date
BR0309406A true BR0309406A (pt) 2005-02-01
BRPI0309406B1 BRPI0309406B1 (pt) 2017-04-11

Family

ID=29265897

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0309406A BRPI0309406B1 (pt) 2002-04-26 2003-04-15 composição farmacêutica, processo para preparar a referida composição, kit para tratamento de obesidade e uso da referida composição na fabricação de composições úteis para o tratamento e prevenção de obesidade

Country Status (20)

Country Link
US (2) US20040033983A1 (pt)
EP (1) EP1501498B1 (pt)
JP (1) JP4234017B2 (pt)
KR (1) KR100625399B1 (pt)
CN (1) CN1325050C (pt)
AR (1) AR039664A1 (pt)
AT (1) ATE453390T1 (pt)
AU (1) AU2003222814B2 (pt)
BR (1) BRPI0309406B1 (pt)
CA (1) CA2483002C (pt)
DE (1) DE60330764D1 (pt)
ES (1) ES2335876T3 (pt)
GT (1) GT200300094A (pt)
MX (1) MXPA04010371A (pt)
PA (1) PA8571901A1 (pt)
PE (1) PE20040596A1 (pt)
PL (1) PL216022B1 (pt)
RU (1) RU2297221C2 (pt)
TW (1) TW200404536A (pt)
WO (1) WO2003090742A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2208496A1 (en) * 2004-08-25 2010-07-21 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
ITMI20050010A1 (it) * 2005-01-05 2006-07-06 Aboca S P A Composizioni farmaceutiche nutraceutiche dietetiche nutrizionali a base di fibre vegetali
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
ATE477820T1 (de) * 2007-09-12 2010-09-15 Mader S R L Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
BRPI0901602B8 (pt) * 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
US9034342B2 (en) * 2010-03-25 2015-05-19 Gateway Health Alliances, Inc Methods and compositions to reduce fat gain, promote weight loss in animals
WO2012070702A1 (ko) * 2010-11-25 2012-05-31 주식회사 삼양사 올리스태트 및 키토산 함유 조성물 및 그 제조방법
US10507194B2 (en) 2015-08-10 2019-12-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treating obesity
CN108524495B (zh) * 2018-07-10 2019-02-26 中山万汉制药有限公司 奥利司他在制备治疗便秘的药物中的用途
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN115671132B (zh) * 2020-06-01 2024-03-15 山东新时代药业有限公司 一种益生菌和益生元的组合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582714A (en) * 1982-07-08 1986-04-15 Mars G.B. Limited Air or oil emulsion food product having glucomannas as sole stabilizer-thickener
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US5477953A (en) * 1992-03-16 1995-12-26 Environmental Products Corporation Filter and filter cleaning system for a reverse vending machine
CA2098167C (en) 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
AU5745394A (en) * 1992-12-30 1994-08-15 Fmc Corporation Readily available konjac glucomannan sustained release excipient
WO1998033395A1 (fr) * 1997-02-03 1998-08-06 Takahisa Shiota Aliment prepare a partir d'un sol de farine de konjak
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US5942500A (en) * 1998-04-27 1999-08-24 Perry; Stephen C. Dietary composition to reduce dietary fats
US6093439A (en) 1998-05-08 2000-07-25 National Starch And Chemical Investment Holding Corporation Hydrocolloid composition for use as a gelling agent viscosifier and stabilizer
EP1105122B1 (en) 1998-08-14 2005-04-27 F.Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
TR200100472T2 (tr) * 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
HU229550B1 (en) * 2000-06-27 2014-01-28 Hoffmann La Roche Method for preparing compositions
PT1307264E (pt) * 2000-07-28 2005-02-28 Hoffmann La Roche Nova composicao farmaceutica
US6558690B2 (en) * 2000-12-15 2003-05-06 Pacific Health Laboratories, Inc. Nutritional composition for improving the efficacy of a lipase inhibitor
JP2004111852A (ja) * 2002-09-20 2004-04-08 Fujitsu Ltd 半導体装置及びその製造方法

Also Published As

Publication number Publication date
EP1501498B1 (en) 2009-12-30
KR20040104626A (ko) 2004-12-10
PE20040596A1 (es) 2004-09-15
CA2483002A1 (en) 2003-11-06
PA8571901A1 (es) 2004-05-26
RU2297221C2 (ru) 2007-04-20
JP2005531536A (ja) 2005-10-20
EP1501498A1 (en) 2005-02-02
KR100625399B1 (ko) 2006-09-20
CN1325050C (zh) 2007-07-11
GT200300094A (es) 2004-01-15
US7816342B2 (en) 2010-10-19
MXPA04010371A (es) 2005-02-03
TW200404536A (en) 2004-04-01
US20040033983A1 (en) 2004-02-19
CA2483002C (en) 2011-02-01
CN1649580A (zh) 2005-08-03
BRPI0309406B1 (pt) 2017-04-11
ES2335876T3 (es) 2010-04-06
ATE453390T1 (de) 2010-01-15
WO2003090742A1 (en) 2003-11-06
PL216022B1 (pl) 2014-02-28
JP4234017B2 (ja) 2009-03-04
US20060135471A1 (en) 2006-06-22
RU2004134573A (ru) 2005-10-10
AR039664A1 (es) 2005-03-02
AU2003222814B2 (en) 2006-08-24
PL373692A1 (en) 2005-09-05
DE60330764D1 (de) 2010-02-11
AU2003222814A1 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
BRPI0410630A (pt) antagonista de nk1
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0310092A (pt) Combinação de compostos orgânicos
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
BRPI0406596A (pt) Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
BR0315355A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, composição farmacêutica e utilização de um inibidor de re-apreensão de norepinefrina
BRPI0406477A (pt) Composição, agente de tratamento de óleo, e, métodos de produção de uma composição e de tratamento de óleo
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/04/2017, OBSERVADAS AS CONDICOES LEGAIS.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 9/48 (2006.01), A61K 31/

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: MANUTENCAO DA EXTINCAO - ART. 78 INCISO IV DA LPI